Læknablaðið - 15.04.2007, Síða 33

YFIRLITSGREIN / NÝRNAFRUMUKRABBAMEIN
52. Perez-Ordonez B, Hamed G, Campbell S, Erlandson RA, Russo
P, Gaudin PB, et al. Renal oncocytoma: a clinicopathologic
study of 70 cases. Am J Surg Pathol 1997; 21:871-83.
53. Romis L, Cindolo L, Patard JJ, Messina G, Altieri V, Salomon
L, et al. Frequency, clinical presentation and evolution of
renal oncocytomas: multicentric experience from a European
database. Eur Urol 2004; 45:53-7; discussion 57.
54. Ritchie AW, Chisholm GD. The natural history of renal
carcinoma. Semin Oncol 1983; 10:390-400.
55. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural
history of renal cell carcinoma. J Urol 2001; 166:1611-23.
56. Sufrin G, Chasan S, Golio A, Murphy GP. Paraneoplastic and
serologic syndromes of renal adenocarcinoma. Semin Urol
1989;7:158-71.
57. Autopsies in Iceland 1981-2002 by sex and age. www.hagstofa.
is Statistics Iceland, Reykjavik 2005.
58. Bos SD, Mellema CT, Mensink HJ. Increase in incidental renal
cell carcinoma in the northern part of the Netherlands. Eur
Urol 2000; 37:267-70.
59. Konnak JW, Grossman HB. Renal cell carcinoma as an
incidental finding. J Urol 1985; 134:1094-6.
60. Lee CT, Katz J, Fearn PA, Russo P. Mode of presentation of
renal cell carcinoma provides prognostic information. Urol
Oncol 2002; 7:135-40.
61. Bretheau D, Koutani A, Lechevallier E, Coulange C. A
French national epidemiologic survey on renal cell carcinoma.
Oncology Committee of the Association Francaise d‘Urologie.
Cancer 1998; 82:538-44.
62. Ficarra V, Righetti R, Pilloni S, D'Amico A, Maffei N, Novella
G, et al. Prognostic factors in patients with renal cell carcinoma:
retrospective analysis of 675 cases. Eur Urol 2002; 41:190-8.
63. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke
H. An outcome prediction model for patients with clear cell
renal cell carcinoma treated with radical nephrectomy based
on tumor stage, size, grade and necrosis: the SSIGN score. J
Urol 2002; 168:2395-400.
64. Gettman MT, Blute ML, Spotts B, Bryant SC, Zincke H.
Pathologic staging of renal cell carcinoma: significance of
tumor classification with the 1997 TNM staging system. Cancer
2001;91:354-61.
65. Robson CJ, Churchill BM, Anderson W. The results of radical
nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297-
301.
66. Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S,
MacLennan G, et al. TNM staging of renal cell carcinoma:
Workgroup No. 3. Union International Contre le Cancer
(UICC) and the American Joint Committee on Cancer
(AJCC). Cancer 1997; 80:992-3.
67. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller
DG, et al., editors. AJCC Cancer Staging Manual. 6th ed.
American Joint Committee on Cancer, Chicago 2002.
68. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal
M, Coulange C. Prognostic value of nuclear grade of renal cell
carcinoma. Cancer 1995; 76:2543-9.
69. Ficarra V, Righetti R, Martignoni G, D‘Amico A, Pilloni S,
Rubilotta E, et al. Prognostic value of renal cell carcinoma
nuclear grading: multivariate analysis of 333 cases. Urol Int
2001;67:130-4.
70. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of
morphologic parameters in renal cell carcinoma. Am J Surg
Pathol 1982; 6:655-63.
71. Ljungberg B. Prognostic factors in renal cell carcinoma. Scand
J Surg 2004;93:118-25.
72. Ljungberg B, Mehle C, Stenling R, Roos G. Heterogeneity
in renal cell carcinoma and its impact no prognosis-a flow
cytometric study. Br J Cancer 1996; 74:123-7.
73. Reznek RH. Imaging in the staging of renal cell carcinoma.
Eur Radiol 1996; 6:120-8.
74. Zagoria RJ. Imaging of small renal masses: a medical success
story. AJR Am J Roentgenol 2000; 175:945-55.
75. Choyke PL. Detection and staging of renal cancer. Magn
Reson Imaging Clin N Am 1997; 5:29-47.
76. Blom JH, van Poppel H, Marechal JM, Jacqmin D, Sylvester
R, Schroder FH, et al. Radical nephrectomy with and without
lymph node dissection: preliminary results of the EORTC
randomized phase III protocol 30881. EORTC Genitourinary
Group. Eur Urol 1999; 36:570-5.
77. Mejean A, Oudard S, Thiounn N. Prognostic factors of renal
cell carcinoma. J Urol 2003; 169:821-7.
78. Tsui KH, Shvarts O, Barbaric Z, Figlin R, de Kernion JB,
Belldegrun A. Is adrenalectomy a necessary component of
radical nephrectomy? UCLA experience with 511 radical
nephrectomies. J Urol 2000; 163:437-41.
79. Nesbitt JC, Soltero ER, Dinney CP, Walsh GL, Schrump
DS, Swanson DA, et al. Surgical management of renal cell
carcinoma with inferior vena cava tumor thrombus. Ann
Thorac Surg 1997; 63:1592-600.
80. Mejean A, Vogt B, Quazza JE, Chretien Y, Dufour B. Mortality
and morbidity after nephrectomy for renal cell carcinoma
using a transperitoneal anterior subcostal incision. Eur Urol
1999; 36:298-302.
81. Beisland C, Medby PC, Sander S, Beisland HO. Nephrectomy
- indications, complications and postoperative mortality in 646
consecutive patients. Eur Urol 2000; 37:58-64.
82. Uzzo RG, Novick AC. Nephron sparing surgery for renal
tumors: indications, techniques and outcomes. J Urol 2001; 166:
6-18.
83. Lemer SE, Hawkins CA, Blute ML, Grabner A, Wollan PC,
Eickholt JT, et al. Disease outcome in patients with low stage
renal cell carcinoma treated with nephron sparing or radical
surgery. J Urol 1996; 155:1868-73.
84. Thoroddsen Á, Einarsson GV, Gíslason Þ, Geirsson G,
Jónsson E, Guöbjartsson T. Hlutabrottnám á nýra vegna
nýrnafrumukrabbameins á íslandi. Læknablaðið 2002; 88:311/
E 04.
85. Licht MR, Novick AC, Goormastic M. Nephron sparing
surgery in incidental versus suspected renal cell carcinoma. J
Urol 1994; 152:39-42.
86. Cohen HT, McGovem FJ. Renal-cell carcinoma. N Engl J Med
2005;353:2477-90.
87. Novick AC. Nephron-sparing surgery for renal cell carcinoma.
Br J Urol 1998; 82:321-4.
88. Dunn MD, Portis AJ, Shalhav AL, Elbahnasy AM, Heidorn
C, McDougalI EM, et al. Laparoscopic versus open radical
nephrectomy: a 9-year experience. J Urol 2000; 164:1153-9.
89. Swanson DA. Surgery for metastases of renal cell carcinoma.
Scand J Surg 2004; 93:150-5.
90. Mickisch GH, Garin A, van Poppel H, de Prijck L,
Sylvester R. Radical nephrectomy plus interferon-alfa-based
immunotherapy compared with interferon alfa alone in
metastatic renal-cell carcinoma: a randomised trial. Lancet
2001; 358:966-70.
91. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H.
Guidelines on renal cell cancer. Eur Urol 2001; 40:252-5.
92. Levy DA, Slaton JW, Swanson DA, Dinney CP. Stage specific
guidelines for surveillance after radical nephrectomy for local
renal cell carcinoma. J Urol 1998; 159:1163-7.
93. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for
advanced renal-cell carcinoma: 1983-1993. Semin Oncol 1995;
22:42-60.
94. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy
V, McGrath PC, et al. Nephrectomy followed by interferon
alfa-2b compared with interferon alfa-2b alone for metastatic
renal-cell cancer. N Engl J Med 2001; 345:1655-9.
95. Collins S, McKiernan J, Landman J. Update on the
epidemiology and biology of renal cortical neoplasms. J
Endourol 2006; 20:975-85.
96. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ,
Hudes GR,et al. Sunitinib in patients with metastatic renal cell
carcinoma. JAMA 2006; 295:2516-24.
97. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels
M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma.
N Engl J Med 2007; 356:125-34.
98. Motzer RJ, Hutson TE,Tomczak P, Michaelson MD, Bukowski
RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic
renal-cell carcinoma. N Engl J Med 2007; 356:115-24.
99. Mouraviev V, Joniau S, Van Poppel H, Polascik TJ. Current
status of minimally invasive ablative techniques in the
treatment of small renal tumours. Eur Urol 2007; 51:328-36.
100. BeisIand C, Medby PC, Beisland HO. Renal cell carcinoma:
gender difference in incidental detection and cancer-specific
survival. Scand J Urol Nephrol 2002; 36:414-8.
Læknablaðið 2007/93 297